A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours (NCT04969835)
A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Cancer Center — New York, New York
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Fred Hutchinson Cancer Center — Seattle, Washington
- The Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde — Glasgow,
- St James's University Hospital, The Leeds Teaching Hospitals NHS Trust — Leeds,
- The Royal Marsden, NHS Foundation Trust — London,
- The Christie NHS Foundation Trust — Manchester,
- The Freeman Hospital, Newcastle-upon-Tyne NHS Foundation Trust — Newcastle upon Tyne,
- Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust — Sheffield,
📞 Contact the Study Coordinator
Phone: +44 (0)20 3911 0353
Email: clinicaltrials@avacta.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Salivary Gland Tumor
- Physiologic MR Imaging of Salivary Gland Tumors — Philadelphia, Pennsylvania
Explore by condition: All Salivary Gland Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.